Rx FOR SURVIVAL
Article Abstract:
The $3 billion Indian pharmaceutical industry is facing a grim situation, and is forced to take up significant decisions to face stiff competition looming ahead. The progressive pharma companies of the country will have to get into licensing agreements with foreign companies in order to survive. Ranbaxy Laboratories has entered into licensing agreement with a Japanese major for Sparfloxacin. The products for which patents have been filed after 1995 are likely to register good sales by the year 2003. These products can enjoy the benefit of patent protection for about 10-12 years. If the Indian government decides to allow exclusive marketing rights (EMR) by April 1999 it could create more problems for the Indian pharma industry. No Indian firm will then be able to sell products patented after 1995 for which multinationals get EMR clearance. (gs) --------------------------------------------------------- Major Drugs Going Off Patent List Till 2005 --------------------------------------------------------- Drugs Company Market size Year (in $ billion) --------------------------------------------------------- Prilosec Astra Merck 3.7 2000 --------------------------------------------------------- Vasotec Merck 2.5 2000 --------------------------------------------------------- Pepcid Merck 1.0 2000 --------------------------------------------------------- Prozac Eli Lilly 2.4 2001 --------------------------------------------------------- Mevacor Merck 1.3 2001 --------------------------------------------------------- Augmentin SmithKline 1.4 2002 --------------------------------------------------------- Procardia Pfizer 2.0 2003 --------------------------------------------------------- Cipro Bayer 1.3 2003 --------------------------------------------------------- Claritin Schering 1.0 2004 --------------------------------------------------------- Zocor Merck 2.8 2005 --------------------------------------------------------- Zoloft Pfizer 1.4 2005 ---------------------------------------------------------
Comment:
India: The $3 bil pharmaceutical ind is facing grim situation & is forced to take up decisions to face competition looming ahead
Publication Name: Economic Times
Subject: Business, international
ISSN: 0013-0389
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
KARNATAKA MALLADI STILL IN SICK BED
Article Abstract:
Karnataka Malladi Biotics Limited of Mandya, belonging to the Malladi group of Chennai, has shown no signs of recovery. Its 150-odd employees are facing an uncertain future. The management shut down the unit in March 1997 owing to financial problems. Around 17 percent stake in Karnataka Malladi is held by the Karnataka State Industrial Investment and Development Corporation (KSIIDC). The company manufactures drugs and pharmaceuticals. Some of its products include, the anti- bronchitic drug ephedrine hydrochloride, the tissutive, pseudo ephedrine hydrochloride and dextromethophone hydrobromide. (gsh)
Comment:
Shows no signs of recovery following closure in 3/97, with 150 of employees facing uncertain future
Publication Name: Economic Times
Subject: Business, international
ISSN: 0013-0389
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
RANBAXY LABORATORIES AMONG WORLD's TOP 100 PHARMA COMPANIES
Article Abstract:
Ranbaxy Laboratories (RL) has emerged as the first Indian company to be listed among the top 100 international pharmaceutical companies. RL has entered the overseas market by opening manufacturing units in Ireland and the US. Promoter Mr Parvinder Singh and his associates hold 32 percent stake in RL. It has posted net profit of $47 million on sales of $335 million for 1997-98. (gs)
Comment:
Emerges as the first Indian company to be listed among the top 100 intnl pharmaceutical companies
Publication Name: Economic Times
Subject: Business, international
ISSN: 0013-0389
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: BRIDGING THE RADIAL GAP INDIA NOW RIDES ON THE WORLD'S NO 1 RADIAL. EUROMEDICA SETS UP SHOP IN INDIA
- Abstracts: THE INDUSTRIAL FINANCE CORPORATION OF INDIA LTD KARNATAKA STATE FINANCIAL CORPORATION
- Abstracts: CENTRAL BANK RECORDS Rs175-CR NET PROFIT UTI TO DIVEST PART OF STAKE IN UTI BANK